甘氨酰-L-谷氨酰胺一水合物 | 13115-71-4

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 谷氨酰胺类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 甘氨酰-L-谷氨酰胺一水合物
• 中文别名: L-甘-谷二肽；甘氨酰-L-谷氨酰胺；甘氨酰-L-谷氨酰胺一水和物；L-甘-谷二肽,甘氨酰-L-谷氨酰胺一水合物；甘氨酰-L-谷氨酰胺单水合物.甘氨酰-L-谷氨酰胺.甘氨酰谷氨酰胺.N-甘氨酰-L-谷氨酰胺.甘氨酰-L-谷氨；甘氨酰-L-谷氨酰胺单水合物；甘氨酰谷氨酰胺；N-甘氨酰-L-谷氨酰胺；甘氨酰谷氨酰胺(甘氨酰-L-谷氨酰胺)；甘氨-L-谷氨酰胺；甘谷二肽
• 英文名称: glycyl-L-glutamine
• 英文别名: L-glycyl-L-glutamine；H2N-glycine-glutamine-OH；glycyl-(S)-glutamine；glycl-L-glutamine；glycyl-glutamine；Gly-gln；(2S)-5-amino-2-[(2-azaniumylacetyl)amino]-5-oxopentanoate
• CAS: 13115-71-4
• 化学式: C₇H₁₃N₃O₄
• 分子量: 203.198
• InChiKey: PNMUAGGSDZXTHX-BYPYZUCNSA-N

物化性质

• 熔点：
  194°C
• 比旋光度：
  -6.5 º (c=10, 2N HCl)
• 沸点：
  643.1±55.0 °C(Predicted)
• 密度：
  1.359±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于酸性水溶液（轻微）、水（轻微）
• LogP：
  -6.25--5.12 at 25℃ and pH1-13
• 表面张力：
  71.9mN/m at 1g/L and 20℃

计算性质

• 辛醇/水分配系数(LogP)：
  -4.6
• 重原子数：
  14
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  136
• 氢给体数：
  4
• 氢受体数：
  5

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S23,S24/25,S26,S37/39
• 危险类别码：
  R36/37/38
• WGK Germany：
  -
• 海关编码：
  2924199090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  2-8°C

SDS

Name:	Glycyl-L-glutamine monohydrate 99% Material Safety Data Sheet
Synonym:	Glutamine (L)-, glycyl
CAS:	13115-71-4

Section 1 - Chemical Product MSDS Name:Glycyl-L-glutamine monohydrate 99% Material Safety Data Sheet
Synonym:Glutamine (L)-, glycyl

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
13115-71-4	Glycyl-L-glutamine monohydrate	99	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use agent most appropriate to extinguish fire. Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Sweep up, then place into a suitable container for disposal. Avoid generating dusty conditions. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low. Use process enclosure, local exhaust ventilation, or other engineering controls to control airborne levels.
Exposure Limits CAS# 13115-71-4: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white
Odor: none reported
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: > 194 deg C
Autoignition Temperature: Not applicable.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature: >160 deg C
Solubility in water: 154 g/l (20 c)
Specific Gravity/Density: Not available.
Molecular Formula: C7H13N3O4.H2O
Molecular Weight: 221.22

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, strong oxidants.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Irritating and toxic fumes and gases.
Hazardous Polymerization: Will not occur.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 13115-71-4 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Glycyl-L-glutamine monohydrate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 13115-71-4: 0
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 13115-71-4 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 13115-71-4 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

制备

以甘氨酸和L-谷氨酰胺为主要原料，先用邻苯二甲酸酐对甘氨酸进行氨基保护，所得中间产物与氯化亚砜生成酰氯，然后再与L-谷氨酰胺酰胺化，最后在甲醇中用水合肼脱保护得到产品。粗品经一次精制即可达到药用级水平。

用途

甘氨酰-L-谷氨酰胺在哺乳动物细胞培养基中作为谷氨酰胺的热稳定性替代物。作为一种氨基酸营养药物，它可用于提高患者细胞免疫功能，并有效降低危重患者的感染风险，尤其是在严重感染、恶性肿瘤等危重病人的治疗和恢复中具有重要作用。该原料药既可以单独作为药物使用，也可以与其他氨基酸复配，还可开发为保健品。

生物活性

Glycyl-glutamine (Glycyl-L-glutamine) 是 β-endorphin 的酶裂解产物，是 β-内啡肽(1-31) 的内源拮抗剂。它是一种比谷氨酰胺 (Gln) 稳定的活性神经肽。

体外研究

甘氨酰-L-谷氨酰胺 (Glycyl-glutamine (Glycyl-L-glutamine)) 是一种含有谷氨酸且具有激活和稳定作用的神经肽。与自由型谷氨酰胺 (Gln) 相比，它在细胞培养过程中，在灭菌和储存期间更适合作为生长因子。

体内研究

甘氨酰-L-谷氨酰胺 (0.3, 0.6, 1.0 和 10.0 nM) 可以剂量依赖性地抑制戊巴比妥麻醉大鼠由 β-End-(1-31) 引起的低血压。

反应信息

• 作为反应物：
  描述：

  甘氨酰-L-谷氨酰胺一水合物 在 哌啶 、 sodium carbonate 、 1-羟基苯并三唑 、 溶剂黄146 、 N,N'-二环己基碳二亚胺 作用下， 以 1,4-二氧六环 、 甲醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 80.17h， 生成 (2S)-2-[[2-(diaminomethylideneamino)acetyl]amino]-N-[[(2R,3S,4R,5S)-5-(2,4-dioxo-1H-pyrimidin-5-yl)-3,4-dihydroxyoxolan-2-yl]methyl]pentanediamide
  参考文献：
  名称：

  [EN] PSEUDOURIDIMYCIN (PUM) AND ITS DERIVATES
  [FR] PSEUDO-URIDIMYCINE (PUM) ET SES DÉRIVÉS

  摘要：

  公开号：

  WO2014024013A8
• 作为产物：
  描述：

  Carbobenzoxy-glycyl-<α-p-nitro-benzyl,γ-methyl>-L-glutamat 在 palladium on activated charcoal ammonium hydroxide 、 氢气 作用下， 以 甲醇 、 水 为溶剂， 生成 甘氨酰-L-谷氨酰胺一水合物
  参考文献：
  名称：

  Studies of the Synthesis of Peptides ContainingC-Terminal Glutamine. II The Synthesis and Use of α-p-Nitrobenzyl γ-Methyl L-Glutamate

  摘要：

  DOI：

  10.1246/bcsj.37.200

文献信息

• Process for producing dipeptides or dipeptide derivatives
  申请人：Hashimoto Shin-ichi

  公开号：US20050287627A1

  公开（公告）日：2005-12-29

  The present invention provides a process for producing a dipeptide or a dipeptide derivative using a phosphate donor, a substance selected from the group consisting of adenosine-5′-monophosphate, adenosine-5′-diphosphate and adenosine-5′-triphosphate, one or more kinds of amino acids or amino acid derivatives, and as enzyme sources, a protein having polyphosphate kinase activity, or a culture of cells having the ability to produce the protein or a treated matter of the culture, and a protein having the activity to ATP-dependently form the dipeptide or dipeptide derivative from one or more kinds of amino acids or amino acid derivatives, or a culture of cells having the ability to produce the protein or a treated matter of the culture.

  本发明提供了一种利用磷酸供体、从腺苷-5′-单磷酸、腺苷-5′-二磷酸和腺苷-5′-三磷酸组成的一组物质中选择的物质、一种或多种氨基酸或氨基酸衍生物，以及作为酶源的具有多磷酸激酶活性的蛋白质，或者具有产生该蛋白质的能力的细胞培养物，以及具有ATP依赖性形成该二肽或二肽衍生物的活性蛋白质，或者具有产生该蛋白质的能力的细胞培养物或经处理的培养物质的生产二肽或二肽衍生物的过程。
• Process for preparing a 3-hydroxy-3-methylbutyrate amino acid salt and method of use.
  申请人：——

  公开号：US20040176449A1

  公开（公告）日：2004-09-09

  This invention relates to a process for the synthesis and method of use of an effective amount of a 3-hydroxy-3-methylbutyrate (HMB) amino acid salt for the regulation athletic function in humans.

  这项发明涉及一种用于合成和使用3-羟基-3-甲基丁酸盐（HMB）氨基酸的有效量的过程和方法，用于调节人类运动功能。
• Process For Producing Dipeptides or Dipeptide Derivatives
  申请人：Hashimoto Shin-ichi

  公开号：US20080213827A1

  公开（公告）日：2008-09-04

  The present invention provides a process for producing a dipeptide or a dipeptide derivative by using a protein having the activity to form the dipeptide or dipeptide derivative from one or more kinds of amino acids or amino acid derivatives, or a culture of cells having the ability to produce the protein or a treated matter of the culture as a enzyme source, which comprise; allowing the enzyme source, one or more kinds of amino acids or amino acid derivatives and ATP to be present in an aqueous medium; allowing the dipeptide or dipeptide derivative to form and accumulate in the medium; and recovering the dipeptide or dipeptide derivative from the medium.

  本发明提供了一种通过利用具有形成二肽或二肽衍生物的活性的蛋白质，从一种或多种氨基酸或氨基酸衍生物中形成二肽或二肽衍生物的过程，或者具有产生该蛋白质的能力的细胞培养物或经处理的培养物作为酶源的方法，包括： 使酶源、一种或多种氨基酸或氨基酸衍生物和ATP存在于水性介质中； 使二肽或二肽衍生物形成并在介质中积累；以及 从介质中回收二肽或二肽衍生物。
• COSMETIC COMPOSITION
  申请人：Knappe Thorsten

  公开号：US20100028272A1

  公开（公告）日：2010-02-04

  A cosmetic agent, in particular a styling agent, containing, in a cosmetically acceptable carrier, a) at least one copolymer A made of at least one monomer A1 selected from acrylic acid, methacrylic acid, acrylic acid alkyl esters, and methacrylic acid alkyl esters, and at least one amphoteric monomer A2 selected from (meth)acryloylalkylbetaines of formula (A2-I) and (meth)acryloylalkylamine oxides of formula (A2-II), such that in formula (A2-I) and in formula (A2-II), R 1 denotes H or CH 3 , R 2 and R 3 , mutually independently in each case, denote optionally branched C 1-10 alkyl, and n denotes an integer from 1 to 20, and b) at least one film-forming and/or setting amphoteric polymer B different from copolymer A; and use of the agents for the temporary deformation of hairs.

  一种化妆品剂，特别是一种造型剂，包含在一种在化妆上可接受的载体中，a) 至少一种由至少一种从丙烯酸、甲基丙烯酸、丙烯酸烷基酯和甲基丙烯酸烷基酯中选择的单体A1制成的共聚物A，以及至少一种从式（A2-I）的（甲基）丙烯酰烷基甜菜碱和式（A2-II）的（甲基）丙烯酰烷基胺氧中选择的两性单体A2，使得在式（A2-I）和式（A2-II）中，R1代表H或CH3，R2和R3，在每种情况下相互独立地表示可选的支链C1-10烷基，n代表1到20之间的整数，以及b) 至少一种与共聚物A不同的成膜和/或固定两性聚合物B；以及使用这些剂对头发进行暂时变形。
• COMPOUNDS AND METHODS FOR DELIVERY OF PROSTACYCLIN ANALOGS
  申请人：United Therapeutics Corporation

  公开号：US20150259274A1

  公开（公告）日：2015-09-17

  This invention pertains generally to prostacyclin formulations and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis.

  这项发明通常涉及前列环素配方及其在促进血管舒张、抑制血小板聚集和血栓形成、刺激溶栓、抑制细胞增殖（包括血管重塑）、提供细胞保护、预防动脉粥样硬化和诱导血管生成方面的用途方法。

表征谱图